Martin R Graf

US Patent:

7264820, Sep 4, 2007

Filed:

Jun 5, 2001

Appl. No.:

09/875823

Inventors:

John C. Hiserodt - Huntington Beach CA, US
Martin R. Graf - Richmond VA, US
Gale A. Granger - Laguna Beach CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39/00

US Classification:

4242771

Abstract:

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

US Patent:

7364726, Apr 29, 2008

Filed:

Jun 5, 2001

Appl. No.:

09/875349

Inventors:

John C. Hiserodt - Huntington Beach CA, US
Martin R. Graf - Richmond VA, US
Gale A. Granger - Laguna Beach CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 48/00

US Classification:

424 932

Abstract:

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

US Patent:

20080057029, Mar 6, 2008

Filed:

Aug 31, 2007

Appl. No.:

11/897993

Inventors:

John Hiserodt - Huntington Beach CA, US
Martin Graf - Richmond VA, US
Gale Granger - Laguna Beach CA, US

International Classification:

A61K 38/19
A61K 38/20
A61K 39/385

US Classification:

424085200, 424193100, 514012000

Abstract:

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

US Patent:

20080075744, Mar 27, 2008

Filed:

Jun 29, 2007

Appl. No.:

11/824480

Inventors:

John Hiserodt - Huntington Beach CA, US
Martin Graf - Richmond VA, US
Gale Granger - Laguna Beach CA, US

International Classification:

A61K 35/00
A61K 39/00
A61P 43/00
C12N 15/87

US Classification:

424277100, 424093210, 435455000

Abstract:

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-α, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.

US Patent:

62773682, Aug 21, 2001

Filed:

Jul 24, 1997

Appl. No.:

8/901225

Inventors:

John C. Hiserodt - Huntington Beach CA
Martin R. Graf - Richmond VA
Gale A. Granger - Laguna Beach CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A01N 6300
C12N 1585
A61K 3512
A61K 3519

US Classification:

424 9321

Abstract:

This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-. alpha. , and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen. Vaccines may be tailored for each type of cancer or for each subject by mixing tumor antigen with a favorable number of cytokine-producing cells, or with a cocktail of such cells producing a plurality of cytokines at a favorable ratio.